• T.O. Kryuchko Ukrainian Medical Stomatological Academy, Poltava, Ukraine
  • O.Ya. Tkachenko Ukrainian Medical Stomatological Academy, Poltava, Ukraine
  • N.V. Kuzmenko Ukrainian Medical Stomatological Academy, Poltava, Ukraine
  • I.N. Nesina Ukrainian Medical Stomatological Academy, Poltava, Ukraine
  • S.M. Tanianska Ukrainian Medical Stomatological Academy, Poltava, Ukraine
  • I.A. Kolenko Ukrainian Medical Stomatological Academy, Poltava, Ukraine
  • M.O. Melnyk Ukrainian Medical Stomatological Academy, Poltava, Ukraine
Keywords: Staphylococcus aureus, virulence factors, bacterial infections


Staphylococcus aureus is a universal bacterial pathogen, which is able to develop the resistance to new antibiotics, by means of virulence factors, whose main function is the spread of diseases by inhibiting the immune factors of host defense. Its wide spread at in-patient departments and also the presence of clinical probationary wards Staphylococcus aureus, resistant to methicillin at out-patient departments, deprive the doctors of effective means for control of the infection. Complications caused by MRSA lead to hospitalization and indices of lethality. The aim of the paper is to analyze the main factors of S. аureus virulence and ways the of its interaction as a result of etiological and pathogenetic treatment. Complexity of treatment of bacterial infections is determined by alternative ways of prevention and treatment of diseases to which bacteria are not able to develop resistance. Along with general mechanisms that form antibiotic resistance, S. aureus produces many individual virulence factors that model the immune response, affecting the survival of the microorganism. The virulence factors produced by S. aureus are diverse and have the ability not only to cause cell lysis, but also to stimulate tissue rejection and destruction. It is important to determine that many specific factors of virulence caused by S. aureus, have ability to change both congenital and adaptive immune reactions including inhibition of complement activation, neutrophils neutralization, phagocytes inhibition. Strategies for inhibiting virulence factors can range from using small inhibitor molecules or full-fledged antibodies to creating toxoids and virulence proteins. Great interest is focused upon those inhibitors that have cross-reactivity with respect to multiple virulence factors, as well as inhibitors, the main target of which is a global regulator with multi-purpose activity, for example, agr operon. Active research into the specific alternative antivirulent treatments for severe diseases caused by S. aureus can potentially settle a number of problems and difficulties of post-antibiotic era.


Download data is not yet available.


1. Chaili S, Cheung AL, Bayer AS, et al. The GraS Sensor in Staphylococcus aureus Mediates Resistance to Host Defense Peptides Differing in Mechanisms of Action. Infect Immun. 2016;84(2):459–466.
2. Kryuchko TA, Tkachenko OYa. Clinical experience of using Streptococcus salivarius K12 in the prevention of pharyngotonsillitis and respiratory infections in children. Child Health. 2018;13(7):629-634.
3. Alksne LE, Projan SJ. Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol. 2000; 11(6):625–36.
4. Gong J, Li D, Yan J, Liu Y, et al. The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine intracranial abscesses model. Brazilian J Infect Dis. 2014;18(5):501–6.
5. Kang CK, Cho JE, Choi YJ, et al. agr dysfunction affects staphylococcal cassette chromosome mec type-dependent clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2015;59(6):3125–3132.
6. Sully EK, Malachowa N, Elmore BO, et al. Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog. 2014;10(6):e1004174.
7. Nielsen A, Manåsson M, Bojer MS, et al. Solonamide B inhibits quorum sensing and reduces Staphylococcus aureus mediated killing of human neutrophils. PLoS One. 2014; 9(1):1–10.
8. Daly SM, Elmore BO, Kavanaugh JS, et al. ω-Hydroxyemodin limits staphylococcus aureus quorum sensing-mediated pathogenesis and inflammation. Antimicrob Agents Chemother. 2015;59(4):2223–2235.
9. Caballero A, Foletti D, Bierdeman M, et al. Effectiveness of Alpha-toxin Fab Monoclonal Antibody Therapy in Limiting the Pathology of Staphylococcus aureus Keratitis. Ocular immunology and inflammation 23 4 (2015): 297-303.
10. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis. 2010;202(7):1050–1058.
11. Rouha H, Badarau A, Visram ZC, et al. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs. 2014;7(1):243–254.
12. Chua KY, Monk IR, Lin YH, et al. Hyperexpression of α-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. BMC Microbiol. 2014;14:31.
13. Cheung GY, Joo HS, Chatterjee SS, Otto M. Phenol-soluble modulins--critical determinants of staphylococcal virulence. FEMS Microbiol Rev. 2014;38(4):698–719.
14. Tsompanidou E, Denham EL, Becher D, et al. Distinct roles of phenol-soluble modulins in spreading of Staphylococcus aureus on wet surfaces. Appl Environ Microbiol. 2013;79(3):886–895.
15. Syed AK, Reed TJ, Clark KL, Boles BR, Kahlenberg JM. Staphlyococcus aureus phenol-soluble modulins stimulate the release of proinflammatory cytokines from keratinocytes and are required for induction of skin inflammation [published correction appears in Infect Immun. 2015 Nov;83(11):4450]. Infect Immun. 2015;83(9):3428–3437.
16. Chen F, Di H, Wang Y, et al. Small-molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence. Nat Chem Biol. 2016; 12(3):174–179.
17. Chatterjee SS, Joo HS, Duong AC, et al. Essential Staphylococcus aureus toxin export system. Nat Med. 2013;19(3):364–367.
18. Huntzinger E, Boisset S, Saveanu C, et al. Staphylococcus aureus RNAIII and the endoribonuclease III coordinately regulate spa gene expression. EMBO J. 2005;24(4):824–835.
19. Shokri R, Salouti M, Zanjani RS. Anti protein A antibody-gold nanorods conjugate: a targeting agent for selective killing of methicillin resistant Staphylococcus aureus using photothermal therapy method. J Microbiol. 2015; 53(2):116–21.
20. Panyala Nagender Reddy, Peña-Méndez Eladia María, Havel Josef. Gold and nano-gold in medicine: overview, toxicology and perspectives. J Appl Biomed. 2009; 7:75–91.
21. Crémieux AC, Saleh-Mghir A, Danel C, et al. α-hemolysin, not panton-valentine leukocidin, impacts rabbit mortality from severe sepsis with methicillin-resistant Staphylococcus aureus osteomyelitis. J Infect Dis. 2014; 209(11):1773–80.
22. Otto MP, Martin E, Badiou C, et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2013 Mar.68:1524–32.
23. Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol. 2014; 12(7):465–78.
24. Chen Y, Yeh AJ, Cheung GY, et al. Basis of virulence in a Panton-Valentine leukocidin-negative community-associated methicillin-resistant Staphylococcus aureus strain. J Infect Dis. 2014;211(3):472–480.
25. Kim T, Choi J, Lee S, Yeo KJ, et al. Structural Studies on the Extracellular Domain of Sensor Histidine Kinase YycG from Staphylococcus aureus and Its Functional Implications. J Mol Biol. 2016 Jul 31;428(15):3074-89.
26. Argudín MÁ, Mendoza MC, Rodicio MR. Food poisoning and Staphylococcus aureus enterotoxins. Toxins (Basel). 2010;2(7):1751–1773.
27. Krakauer T, Stiles BG. The staphylococcal enterotoxin (SE) family: SEB and siblings. Virulence. 2013;4(8):759–773.
28. Bavari S, Ulrich RG, LeClaire RD. Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens. J Infect Dis. 1999; 180(4):1365–1369.
29. Inskeep TK, Stahl C, Odle J, et al. Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model. Clin Vaccine Immunol. 2010;17(8):1163–1169.
30. Reddy PN, Paul S, Sripathy MH, Batra HV. Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model. Toxicon. 2015; 103:106–13.
31. Flack CE, Zurek OW, Meishery DD, et al. Differential regulation of staphylococcal virulence by the sensor kinase SaeS in response to neutrophil-derived stimuli. Proc Natl Acad Sci U S A. 2014;111(19):E2037–E2045.
32. Long DR, Mead J, Hendricks JM, Hardy ME, Voyich JM. 18β-Glycyrrhetinic acid inhibits methicillin-resistant Staphylococcus aureus survival and attenuates virulence gene expression. Antimicrob Agents Chemother. 2013;57(1):241–247.
33. Parsons JB, Kukula M, Jackson P, et al. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother. 2013;57(5):2182–2190.
34. Okada A, Igarashi M, Okajima T, et al. Walkmycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth. J Antibiot. 2010; 63(2):89–94.
35. Igarashi M, Watanabe T, Hashida T, et al. Waldiomycin, a novel WalK-histidine kinase inhibitor from Streptomyces sp. MK844-mF10. J Antibiot (Tokyo). 2013 Aug;66(8):459-464.
36. Marshall JH, Wilmoth GJ. Pigments of Staphylococcus aureus, a series of triterpenoid carotenoids. J Bacteriol. 1981;147(3):900–913.
How to Cite
Kryuchko, T., Tkachenko, O., Kuzmenko, N., Nesina, I., Tanianska, S., Kolenko, I., & Melnyk, M. (2019). MODERN APPROACHES TO ANTIVIRULENT THERAPY OF DISEASES ASSOCIATED WITH STAPHYLOCOCCUS AUREUS. The Medical and Ecological Problems, 23(3-4), 26-31.